

#### **Plasma derived products demand**

#### **A Canadian perspective**

Sylvain Grenier, B Pharm, PharmD, FFIP, FOPQ Director, PPRP Formulary Program



## Outline

#### **Canadian Blood Services Overview**

#### Impact of the pandemic

Plasma Derived Products

- Immunoglobulins
- C1-esterase inhibitors
- Fibrinogen concentrate
- Bypassing agents

#### **Plasma Sufficiency**



#### **Our locations**

Canadian

Services

& TISSUES

Blood



#### Introductory Overview: Plasma Protein and Related Products (PPRP) formulary

- Plasma Protein and Related Products (synthetic alternatives)
- Bulk purchase about 50 brands worth ~ \$800M annually
- Mainly public tendering process
- Equity of access for patients across the country





## Impact of the pandemic

- Overall decrease in demand
- Hospital use decreased due to deprioritizing of surgeries and other treatments
- Home use saw a significant increase in demand early in the pandemic (March 2020) followed by a significant decrease
- Demand has not recovered yet



## Immunoglobulins





### **C1 Esterase-inhibitors**





#### Fibrinogen concentrate





## **Bypassing agents**





# Canada is one of the highest users of immunoglobulin per capita

- In the last 10 years, Canada's rate of usage for immunoglobulin (Ig) has increased **111 per cent**
- Ig consumption rate approx. 219 g per 1,000 population
- Canadian plasma sufficiency rate for Ig is now at 15 per cent







# Canada's goal is to grow from 15 to 50 per cent sufficiency for immunoglobulin as quickly as possible







#### **Questions?**



# Canadian Blood Services

BLOOD PLASMA STEM CELLS ORGANS & TISSUES